Docetaxel Combined with Epirubicin in the treatment of advanced breast cancer.docVIP

 PAGE \* MERGEFORMAT 4 Docetaxel Combined with Epirubicin in the treatment of advanced breast cancer [Abstract] Objective To observe the Docetaxel Combined with Epirubicin treatment of advanced breast cancer clinical efficacy and toxicity, and safety evaluation. Methods Docetaxel Combined with Epirubicin treatment of advanced breast cancer 56 cases, of which 25 cases of newly diagnosed patients, re-treatment in 31 patients. Solid tumor with the WHO standards and the anti-tumor effect of the recent objective of acute and subacute toxicity of indexing criteria to evaluate the efficacy and toxicity evaluation of physical conditions change with the card. Results in 56 patients, 4 patients achieved complete remission and 27 cases of partial remission, 13 patients in stable condition, 12 cases to show progress, of which the effective rate was 55.36%, clinical benefit rate of 78.57%. Initial treatment and retreatment of patients with no significant difference in efficiency. Toxicity to the gastrointestinal tract reaction and bone marrow suppression mainly mostly Ⅰ ~ Ⅱ degrees. Conclusion Docetaxel Epirubicin in advanced breast cancer have a good efficacy and tolerance, can be used as the treatment of advanced breast cancer. [Keywords:] with advanced breast cancer; Docetaxel; Epirubicin Abstract: Objective To evaluate the efficacy, toxicity and safety of docetaxel and epirubicin in the treatment of advanced breast cancer. Method A total of 56 patients with advanced breast cancer proved pathologically were treated on with docetaxel and epirubicin regimen, among them 25 patients were subjected to initially trertment, other 31 to re-treatment. The response rate and toxicity were evaluated by WHO toxicity scale and performance status by Karnofsky scale. Results Of the 56 patients, 4 achieved CR, 27 PR, 13 SD and 12 PD, with a response rate and clinical benefit rate of 55.36% and 78.57%. There was no significantly difference between initially treated patients and retre